Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection - PubMed (original) (raw)
Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection
Yaa-Hui Dong et al. JAMA Intern Med. 2020.
Abstract
Importance: Prior observational studies have suggested that fluoroquinolone use may be associated with more than 2-fold increased risk of aortic aneurysm or aortic dissection (AA/AD). These studies, however, did not fully consider the role of coexisting infections and the risk of fluoroquinolones relative to other antibiotics.
Objective: To estimate the risk of AA/AD associated with infections and to assess the comparative risk of AA/AD associated with fluoroquinolones vs other antibiotics with similar indication profiles among patients with the same types of infections.
Designs, settings, and participants: This nested case-control study identified 21 651 176 adult patients from a nationwide population-based health insurance claims database from January 1, 2009, to November 30, 2015. Each incident case of AA/AD was matched with 10 control individuals by age, sex, and follow-up duration in the database using risk-set sampling. Analysis of the data was conducted from April 2019 to March 2020.
Exposures: Infections and antibiotic use within a 60-day risk window before the occurrence of AA/AD.
Main outcomes and measures: Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% CIs comparing infections for which fluoroquinolones are commonly used with no infection within a 60-day risk window before outcome occurrence, adjusting for baseline confounders and concomitant antibiotic use. The adjusted ORs comparing fluoroquinolones with antibiotics with similar indication profiles within patients with indicated infections were also estimated.
Results: A total of 28 948 cases and 289 480 matched controls were included (71.37% male; mean [SD] age, 67.41 [15.03] years). Among these, the adjusted OR of AA/AD for any indicated infections was 1.73 (95% CI, 1.66-1.81). Septicemia (OR, 3.16; 95% CI, 2.63-3.78) and intra-abdominal infection (OR, 2.99; 95% CI, 2.45-3.65) had the highest increased risk. Fluoroquinolones were not associated with an increased AA/AD risk when compared with combined amoxicillin-clavulanate or combined ampicillin-sulbactam (OR, 1.01; 95% CI, 0.82-1.24) or with extended-spectrum cephalosporins (OR, 0.88; 95% CI, 0.70-1.11) among patients with indicated infections. The null findings for fluoroquinolone use remained robust in different subgroup and sensitivity analyses.
Conclusions and relevance: These results highlight the importance of accounting for coexisting infections while examining the safety of antibiotics using real-world data; the findings suggest that concerns about AA/AD risk should not deter fluoroquinolone use for patients with indicated infections.
Conflict of interest statement
Conflict of Interest Disclosures: Dr Chang reported receiving grants from the Ministry of Science and Technology, Taiwan, during the conduct of the study and outside the submitted work. No other disclosures were reported.
Figures
Figure.. Risk of Aortic Aneurysm and Aortic Dissection Associated With Fluoroquinolone Monotherapy vs Comparison Antibiotic Monotherapy Among Patients With Indicated Infections Restricted to Those With Potentially High-risk Characteristics
Odds ratios (ORs) are adjusted for matching factors of age, sex, duration of follow-up in the database, and type of infection and for baseline covariates, including hypertension, ischemic heart disease, valve disorder, ischemic stroke, disorders of lipid metabolism, chronic obstructive pulmonary disease, chronic kidney disease, Charlson comorbidity score, tobacco smoking, claims-based frailty index, any episodes of infections, any use of fluoroquinolones, and any use of nonfluoroquinolone antibiotics measured between cohort entry and 60 days before the index date.
Comment in
- Observational Study Design Challenges-The Case of Fluoroquinolones and Aortic Disease.
DeGette RL, Grant RW, Mph MD. DeGette RL, et al. JAMA Intern Med. 2020 Dec 1;180(12):1605-1606. doi: 10.1001/jamainternmed.2020.4191. JAMA Intern Med. 2020. PMID: 32897290 No abstract available. - Fluoroquinolones vs. amoxicillin-clavulanate or ampicillin-sulbactam were not linked to aortic aneurysm or dissection.
Fekete T. Fekete T. Ann Intern Med. 2021 Feb;174(2):JC22. doi: 10.7326/ACPJ202102160-022. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524287 - Fluoroquinolones and Aortic Disease-Reply.
Dong YH, Wang JL, Lin JW. Dong YH, et al. JAMA Intern Med. 2021 Jun 1;181(6):881-882. doi: 10.1001/jamainternmed.2020.9220. JAMA Intern Med. 2021. PMID: 33646261 No abstract available.
Similar articles
- Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection.
Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Gopalakrishnan C, et al. JAMA Intern Med. 2020 Dec 1;180(12):1596-1605. doi: 10.1001/jamainternmed.2020.4199. JAMA Intern Med. 2020. PMID: 32897307 Free PMC article. - Association of Fluoroquinolone Use With Short-term Risk of Development of Aortic Aneurysm.
Newton ER, Akerman AW, Strassle PD, Kibbe MR. Newton ER, et al. JAMA Surg. 2021 Mar 1;156(3):264-272. doi: 10.1001/jamasurg.2020.6165. JAMA Surg. 2021. PMID: 33404647 Free PMC article. - Oral Fluoroquinolone and the Risk of Aortic Dissection.
Lee CC, Lee MG, Hsieh R, Porta L, Lee WC, Lee SH, Chang SS. Lee CC, et al. J Am Coll Cardiol. 2018 Sep 18;72(12):1369-1378. doi: 10.1016/j.jacc.2018.06.067. J Am Coll Cardiol. 2018. PMID: 30213330 - Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection.
Jun C, Fang B. Jun C, et al. BMC Cardiovasc Disord. 2021 Sep 28;21(1):470. doi: 10.1186/s12872-021-02258-1. BMC Cardiovasc Disord. 2021. PMID: 34583637 Free PMC article. Review. - Fluoroquinolones and the Risk of Aortopathy: A Systematic Review and Meta-Analysis.
Latif A, Ahsan MJ, Kapoor V, Lateef N, Malik SU, Patel AD, Khan BA, Bittner M, Holmberg M. Latif A, et al. WMJ. 2020 Sep;119(3):185-189. WMJ. 2020. PMID: 33091293 Review.
Cited by
- Effect of FluoRoquinolones on Aortic Growth, aortic stIffness and wave refLEctionS (FRAGILES study).
Gardikioti V, Georgakopoulos C, Solomou E, Lazarou E, Fasoulakis K, Terentes-Printzios D, Tsioufis K, Iliopoulos D, Vlachopoulos C. Gardikioti V, et al. Life (Basel). 2024 Aug 9;14(8):992. doi: 10.3390/life14080992. Life (Basel). 2024. PMID: 39202735 Free PMC article. - Ciprofloxacin exacerbates dysfunction of smooth muscle cells in a microphysiological model of thoracic aortic aneurysm.
Xiang B, Abudupataer M, Liu G, Zhou X, Liu D, Zhu S, Ming Y, Yin X, Yan S, Sun Y, Lai H, Wang C, Li J, Zhu K. Xiang B, et al. JCI Insight. 2023 Jan 24;8(2):e161729. doi: 10.1172/jci.insight.161729. JCI Insight. 2023. PMID: 36472912 Free PMC article. - Fluoroquinolone antibiotics and adverse events.
Baggio D, Ananda-Rajah MR. Baggio D, et al. Aust Prescr. 2021 Oct;44(5):161-164. doi: 10.18773/austprescr.2021.035. Epub 2021 Oct 1. Aust Prescr. 2021. PMID: 34728881 Free PMC article. Review. - The Expression Patterns and Roles of Lysyl Oxidases in Aortic Dissection.
Yi X, Zhou Y, Chen Y, Feng X, Liu C, Jiang DS, Geng J, Li X, Jiang X, Fang ZM. Yi X, et al. Front Cardiovasc Med. 2021 Jul 7;8:692856. doi: 10.3389/fcvm.2021.692856. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34307505 Free PMC article.
References
- von Allmen RS, Anjum A, Powell JT. Incidence of descending aortic pathology and evaluation of the impact of thoracic endovascular aortic repair: a population-based study in England and Wales from 1999 to 2010. Eur J Vasc Endovasc Surg. 2013;45(2):154-159. doi:10.1016/j.ejvs.2012.12.007 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous